213 related articles for article (PubMed ID: 36927210)
1. Radiomics and theranostics with molecular and metabolic probes in prostate cancer: toward a personalized approach.
Filippi L; Urso L; Bianconi F; Palumbo B; Marzola MC; Evangelista L; Schillaci O
Expert Rev Mol Diagn; 2023 Mar; 23(3):243-255. PubMed ID: 36927210
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments.
Farolfi A; Fendler W; Iravani A; Haberkorn U; Hicks R; Herrmann K; Walz J; Fanti S
Eur Urol Oncol; 2019 Mar; 2(2):152-162. PubMed ID: 31017091
[TBL] [Abstract][Full Text] [Related]
4. A 2022 International Survey on the Status of Prostate Cancer Theranostics.
Beyer T; Czernin J; Freudenberg L; Giesel F; Hacker M; Hicks RJ; Krause BJ
J Nucl Med; 2023 Jan; 64(1):47-53. PubMed ID: 35953304
[TBL] [Abstract][Full Text] [Related]
5. The Role of PSMA PET Imaging in Prostate Cancer Theranostics: A Nationwide Survey.
Borkowetz A; Linxweiler J; Fussek S; Wullich B; Saar M;
Urol Int; 2022; 106(11):1126-1135. PubMed ID: 36195073
[TBL] [Abstract][Full Text] [Related]
6. A systematic review on the current status of PSMA-targeted imaging and radioligand therapy.
Capasso G; Stefanucci A; Tolomeo A
Eur J Med Chem; 2024 Jan; 263():115966. PubMed ID: 37992520
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific membrane antigen (PSMA)-ligand positron emission tomography and radioligand therapy (RLT) of prostate cancer.
Tateishi U
Jpn J Clin Oncol; 2020 Apr; 50(4):349-356. PubMed ID: 32147685
[TBL] [Abstract][Full Text] [Related]
8. Theranostics of Metastatic Prostate Cancer Applying
Mirzaei S; Mohammed F; Zandieh S
Curr Radiopharm; 2021; 14(4):354-358. PubMed ID: 32900357
[TBL] [Abstract][Full Text] [Related]
9. PSMA Theranostics: A "Must Have" in Every Prostate Cancer Center. Illustration of Two Clinical Cases and Review of the Literature.
Cytawa W; Hartrampf P; Lass P; Kircher M; Polat B; Buck AK; Lapa C
Clin Genitourin Cancer; 2021 Aug; 19(4):e235-e247. PubMed ID: 33906800
[TBL] [Abstract][Full Text] [Related]
10. Molecular Imaging and Precision Medicine in Prostate Cancer.
Ceci F; Fiorentino M; Castellucci P; Fanti S
PET Clin; 2017 Jan; 12(1):83-92. PubMed ID: 27863569
[TBL] [Abstract][Full Text] [Related]
11. European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer.
Oprea-Lager DE; MacLennan S; Bjartell A; Briganti A; Burger IA; de Jong I; De Santis M; Eberlein U; Emmett L; Fizazi K; Gillessen S; Herrmann K; Heskamp S; Iagaru A; Jereczek-Fossa BA; Kunikowska J; Lam M; Nanni C; O'Sullivan JM; Panebianco V; Sala E; Sathekge M; Sosnowski R; Tilki D; Tombal B; Treglia G; Tunariu N; Walz J; Yakar D; Dierckx R; Sartor O; Fanti S
Eur Urol; 2024 Jan; 85(1):49-60. PubMed ID: 37743194
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy.
Arsenault F; Beauregard JM; Pouliot F
Curr Opin Support Palliat Care; 2018 Sep; 12(3):359-365. PubMed ID: 29939893
[TBL] [Abstract][Full Text] [Related]
13. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
[TBL] [Abstract][Full Text] [Related]
14. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific membrane antigen-directed imaging and radioguided surgery with single-photon emission computed tomography: state of the art and future outlook.
Filippi L; Palumbo B; Frantellizzi V; Nuvoli S; De Vincentis G; Spanu A; Schillaci O
Expert Rev Med Devices; 2022 Nov; 19(11):815-824. PubMed ID: 36370108
[TBL] [Abstract][Full Text] [Related]
16. Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer.
Giovacchini G; Giovannini E; Riondato M; Ciarmiello A
Curr Radiopharm; 2017; 10(1):6-15. PubMed ID: 28034291
[TBL] [Abstract][Full Text] [Related]
17. Utility of PET to Appropriately Select Patients for PSMA-Targeted Theranostics.
Eshghi A; Covington MF; Eshghi N; Kuo PH
Clin Nucl Med; 2022 Jun; 47(6):488-495. PubMed ID: 35384904
[TBL] [Abstract][Full Text] [Related]
18. New aspects of molecular imaging in prostate cancer.
Ceci F; Castellucci P; Cerci JJ; Fanti S
Methods; 2017 Nov; 130():36-41. PubMed ID: 28711565
[TBL] [Abstract][Full Text] [Related]
19. Current status of radioligand therapy and positron-emission tomography with prostate-specific membrane antigen.
Inubushi M; Miura H; Kuji I; Ito K; Minamimoto R
Ann Nucl Med; 2020 Dec; 34(12):879-883. PubMed ID: 33175360
[TBL] [Abstract][Full Text] [Related]
20. A Prospective Comparison of
Anttinen M; Ettala O; Malaspina S; Jambor I; Sandell M; Kajander S; Rinta-Kiikka I; Schildt J; Saukko E; Rautio P; Timonen KL; Matikainen T; Noponen T; Saunavaara J; Löyttyniemi E; Taimen P; Kemppainen J; Dean PB; Blanco Sequeiros R; Aronen HJ; Seppänen M; Boström PJ
Eur Urol Oncol; 2021 Aug; 4(4):635-644. PubMed ID: 32675047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
